Evidence map›Paper›PMID 42800804›Full record

ArticleBlood cancer journal2026

Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia.

Paul J Hampel, Ying Huang, John N Allan, Seema A Bhat, David Bond, Danielle M Brander, John C Byrd, Julio C Chavez, Elise Chong, Alexey Danilov and 24 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Paul J HampelDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-1292-3024
Ying HuangDivision of Hematology, The Ohio State University, Columbus, OH, USA.
John N AllanDivision of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA.
Seema A BhatDivision of Hematology, The Ohio State University, Columbus, OH, USA.
David BondDivision of Hematology, The Ohio State University, Columbus, OH, USA.
Danielle M BranderDivision of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.
John C ByrdUPMC Cancer Center and Department of Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Julio C ChavezDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
Elise ChongUniversity of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-8895-1625
Alexey DanilovCity of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-4461-0970
Matthew S DavidsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4529-2003
Kaitlyn Dvorak-KornausDivision of Hematology, The Ohio State University, Columbus, OH, USA.
Hannah FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nikita MalakhovDivision of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA.
Matthew MatasarDivision of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Cecelia MillerDivision of Pathology, The Ohio State University, Columbus, OH, USA.
Sarah MillerDivision of Hematology, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0009-0006-9683-8423
Zulfa OmerDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Sameer A ParikhDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-3221-7314
Erin M ParryDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kari G RabeDepartment of Quantitative Health Sciences, Division of Clinic Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-7313-1875
Phil RaessCenter for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0002-6841-4993
Manoj RaiCenter for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Joanna M RhodesDivision of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Kerry A RogersDivision of Hematology, The Ohio State University, Columbus, OH, USA.
Aditi SahaDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
Jake SchadeDivision of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Geoffrey ShouseCity of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-7917-5713
Stephen SpurgeonCenter for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Deborah StephensDivision of Hematology, University of North Carolina, Capel Hill, NC, USA.ORCID http://orcid.org/0000-0001-9188-5008
Yucai WangDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-1576-8341
Jennifer A WoyachDivision of Hematology, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-3403-9144
Max YanoCollege of Medicine, The Ohio State University, Columbus, OH, USA.
Adam S KittaiNew York University Langone Health, Perlmutter Cancer Center, New York, NY, USA. adam.kittai@nyulangone.org.ORCID http://orcid.org/0000-0002-4891-6144

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42800804
PMCPMC13615961

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.